الفهرس | Only 14 pages are availabe for public view |
Abstract Background: chronic kidney disease (CKD) is considered a major health problem with dysregulated phosphate metabolism as a common consequence. Fibroblast Growth Factor -23 (FGF-23) is a hormone, whose major function is to inhibit renal tubular phosphate reabsorption.The Sodium/Hydrogen exchanger regulatory factor-1 (NHERF1)is a scaffolding protein that isimportant in the regulation of protein trafficking,where it increases the abundance of the main renal phosphate transporter (NaPi-IIa) in the apical membrane of proximal tubular cells. Aim of work: The aim of the present study is to investigate the clinical relevance of NHERF1 geneexpression in peripheral blood as well as FGF-23 serum level in patients with end stage renal disease before and 6 months after renal transplantation and their probable association with phosphate level. Subjects and Methods:The present study was carried out prospectively on 37 consecutive adult patientswith end stage renal disease who underwent renal transplantationin which patients of the study were as follow:Patients before transplantation: including 37 patients with end stage renal disease before transplantation. Patients after transplantation: including same patients 6 months afterdoing renal transplantation. FGF-23 serum level was measured using Enzyme Linked Immunosorbent Assay. NHERF1 gene expression was determined by Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) |